, Volume 6, Issue 1, pp 197–205 | Cite as

Australian University Students’ Attitudes Towards the Acceptability and Regulation of Pharmaceuticals to Improve Academic Performance

  • Stephanie Bell
  • Brad Partridge
  • Jayne Lucke
  • Wayne Hall
Original Paper


There is currently little empirical information about attitudes towards cognitive enhancement - the use of pharmaceutical drugs to enhance normal brain functioning. It is claimed this behaviour most commonly occurs in students to aid studying. We undertook a qualitative assessment of attitudes towards cognitive enhancement by conducting 19 semi-structured interviews with Australian university students. Most students considered cognitive enhancement to be unacceptable, in part because they believed it to be unethical but there was a lack of consensus on whether it was similar or different to steroid use in sport. There was support for awareness campaigns and monitoring of cognitive enhancement use of pharmaceutical drugs. An understanding of student attitudes towards cognitive enhancement is important in formulating future policy.


Cognitive enhancement Neuroenhancement Attitudes Qualitative research Stimulants 


  1. 1.
    Sahakian, B.J., and S. Morein-Zamir. 2011. Neuroethical issues in cognitive enhancement. Journal of Psychopharmacology 25(2): 197–204.CrossRefGoogle Scholar
  2. 2.
    Pieters, T., and S. Snelders. 2009. Psychotropic drug use: between healing and enhancing the mind. Neuroethics 2(2): 63–73.CrossRefGoogle Scholar
  3. 3.
    Bostrom, N., and A. Sandberg. 2009. Cognitive enhancement: methods, ethics, regulatory challenges. Science and Engineering Ethics 15(3): 311–341.CrossRefGoogle Scholar
  4. 4.
    Schermer, M. 2008. On the argument that enhancement is "cheating". Journal of Medical Ethics 34(2): 85–88.CrossRefGoogle Scholar
  5. 5.
    McCabe, S.E., J.R. Knight, C.J. Teter, and H. Wechsler. 2005. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 100(1): 96–106.CrossRefGoogle Scholar
  6. 6.
    Franke, A.G., C. Bonertz, M. Christmann, M. Huss, A. Fellgiebel, E. Hildt, and K. Lieb. 2011. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 44(2): 60–66.CrossRefGoogle Scholar
  7. 7.
    Lucke, J.C., S. Bell, B. Partridge, and W.D. Hall. 2011. Deflating the Neuroenhancement Bubble. AJOB Neuroscience 2(4): 38–43.CrossRefGoogle Scholar
  8. 8.
    Chatterjee, A. 2009. Is it acceptable for people to take methylphenidate to enhance performance? British Medical Journal 338: 1532–1533.CrossRefGoogle Scholar
  9. 9.
    Forlini, C., and E. Racine. 2009. Autonomy and coercion in academic "cognitive enhancement" using methylphenidate: perspectives of key stakeholders. Neuroethics 2(3): 163–177.CrossRefGoogle Scholar
  10. 10.
    Forlini, C., and E. Racine. 2010. Stakeholder perspectives and reactions to “academic” cognitive enhancement: unsuspected meaning of ambivalence and analogies. Public Understanding of Science. doi:10.1177/0963662510385062.
  11. 11.
    Appel, J.M. 2008. When the boss turns pusher: a proposal for employee protections in the age of cosmetic neurology. Joural of Medical Ethics 34(8): 616–618.CrossRefGoogle Scholar
  12. 12.
    Schoomaker, E.B. 2007. Military medical research on cognitive performance: the warfighter's competitive edge. Aviation, Space, and Environmental Medicine. Special Issue: Operational applications of cognitive performance enhancement technologies 78(5, Sect II, Suppl): B4–B6.Google Scholar
  13. 13.
    Warren, O.J., D.R. Leff, T. Athanasiou, C. Kennard, and A. Darzi. 2009. The neurocognitive enhancement of surgeons: an ethical perspective. Journal of Surgical Research 152(1): 167–172.CrossRefGoogle Scholar
  14. 14.
    Dees, R.H. 2007. Better brains, better selves? The ethics of neuroenhancements. Kennedy Institute of Ethics Journal 17(4): 371–395.CrossRefGoogle Scholar
  15. 15.
    DeSantis, A., S.M. Noar, and E.M. Webb. 2010. Speeding through the frat house: a qualitative exploration of nonmedical ADHD stimulant use in fraternities. Journal of Drug Education 40(2): 157–171.CrossRefGoogle Scholar
  16. 16.
    DeSantis, A.D., and A.C. Hane. 2010. "Adderall is definitely not a drug": justifications for the illegal use of ADHD stimulants. Substance Use & Misuse 45(1–2): 31–46.CrossRefGoogle Scholar
  17. 17.
    DeSantis, A., E.M. Webb, and S.M. Noar. 2008. Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. Journal of American College Health 57(3): 315–324.CrossRefGoogle Scholar
  18. 18.
    Cakic, V. 2009. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology. Journal of Medical Ethics 35(10): 611–615.CrossRefGoogle Scholar
  19. 19.
    Greely, H., B. Sahakian, J. Harris, R.C. Kessler, M. Gazzaniga, P. Campbell, and M.J. Farah. 2008. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456(7223): 702–705.CrossRefGoogle Scholar
  20. 20.
    Singh, I., and K.J. Kelleher. 2010. Neuroenhancement in young people: proposal for research, policy, and clinical management. AJOB Neuroscience 1(1): 3–16.CrossRefGoogle Scholar
  21. 21.
    DeSantis, A., S.M. Noar, and E.M. Webb. 2009. Nonmedical ADHD stimulant use in fraternities. Journal of Studies on Alcohol and Drugs 70(6): 952–954.Google Scholar
  22. 22.
    Hansen, E.C. 2006. Successful qualitative health research. Crows Nest, NSW: Allen & Unwin.Google Scholar
  23. 23.
    Hill, C.E., S. Knox, B.J. Thompson, E.N. Williams, S.A. Hess, and N. Ladany. 2005. Consensual qualitative research: an update. Journal of Counseling Psychology 52(2): 196–205.CrossRefGoogle Scholar
  24. 24.
    Hill, C.E., B.J. Thompson, and E.N. Williams. 1997. A guide to conducting consensual qualitative research. The Counseling Psychologist 25(4): 517–572.CrossRefGoogle Scholar
  25. 25.
    Fox, N.J., and K.J. Ward. 2008. Pharma in the bedroom … and the kitchen … the pharmaceuticalisation of daily life. Sociology of Health & Illness 30(6): 856–868.CrossRefGoogle Scholar
  26. 26.
    Hall, W. 2004. Feeling 'better than well:' can our experiences with psychoactive drugs help us to meet the challenges of novel neuroenhancement methods? EMBO Reports 5(12): 1105–1109.CrossRefGoogle Scholar
  27. 27.
    Farah, M.J. 2002. Emerging ethical issues in neuroscience. Nature Neuroscience 5(11): 1123–1129.CrossRefGoogle Scholar
  28. 28.
    Forlini, C., and E. Racine. 2009. Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Medical Ethics 10: 9. doi:10.1186/1472-6939-10-9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Stephanie Bell
    • 1
  • Brad Partridge
    • 1
  • Jayne Lucke
    • 1
  • Wayne Hall
    • 1
  1. 1.UQ Centre for Clinical ResearchThe University of QueenslandBrisbaneAustralia

Personalised recommendations